Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 825-837

  Van, Sang ^a   Das, Sanjib K ^a   Wang, Xinghe ^a   Feng, Zhongling ^a   Jin, Yi ^a   Hou, Zheng ^a   Chen, Fu ^a   Pham, Annie ^a   Jiang, Nan ^a   Howell, Stephen B ^b   Yu, Lei ^a  

^a Biomedical Group   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Anticancer; Nanoconjugates; Nanoparticles; Poly(L glutamyl glutamine) paclitaxel; Poly(L glutamic acid)

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTAMIC ACID; NANOPARTICLE; PACLITAXEL POLIGLUMEX; PACLITAXEL POLY(GAMMA GLUTAMYL GLUTAMINE) CONJUGATE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NANOCONJUGATE; PACLITAXEL; POLY(GAMMA GLUTAMYLGLUTAMINE)PACLITAXEL; POLY(GAMMA-GLUTAMYLGLUTAMINE)PACLITAXEL; POLYGLUTAMIC ACID; PROTEIN;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NANOANALYSIS; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; ANIMAL; CHEMISTRY; LUNG TUMOR; METHODOLOGY; NANOMEDICINE; NUDE MOUSE; SOLUBILITY; SYNTHESIS; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOCONJUGATES; NANOMEDICINE; PACLITAXEL; PARTICLE SIZE; POLYGLUTAMIC ACID; PROTEINS; SOLUBILITY;

EID: 79251519910     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S13482     Document Type: Article

References (27)

1. diMasi JA, Hansen RW, Grabowki HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-185.
2. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278-287.
3. Ansari MJ, Kohli K, Dixit N. Microemulsions as potential drug delivery systems: a review. PDA J Pharm Sci Technol. 2008;62;66-79.
4. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347-360.
5. Haag R, Kratz F. Polymer therapeutics: concept and applications. Angew Chem Int Ed Engl. 2006;45:1198-1215.
6. Li C, Yu D-Y, Newman RA, et al. Complete regression of wellestablished tumors using a novel water-soluble poly(L-glutamic acid)- paclitaxel conjugate. Cancer Res. 1998;58:2404-2409.
7. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039-3051.
8. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polymer Symp. 1975;51:135-153.
9. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191-202.
10. Kim T-Y, Kim D-W, Chung J-Y, et al. Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708-3716.
11. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, paclitaxelincorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92:1240-1246.
12. Negishi T, Koizumi F, Uchino H, et al. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to fee paclitaxel. Br J Cancer. 2006;95:601-606.
13. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release. 2001;74:295-302.
14. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91:1775-1781.
15. Nishiyama N, Kataoka K. Preparation and characterization of size- controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J Control Release. 2001;74:83-94.
16. Nishiyama N, Okazaki S, Cbral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003;63:8977-8983.
17. Uchino H, Matsumura Y, Negishi T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005;93:678-787.
18. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991;83:757-766.
19. Veronese ML, Flaherty K, Kramer A, et al. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005;55:497-501.
20. Boddy VA, Plummer RE, Todd R, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res. 2005;11: 7834-7840.
21. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004;22:4523-4531.
22. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase II trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:623-630.
23. Mathew AE, Mejillano MR, Nath JP, Himes RH, Stella VJ. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem. 1992;35:145-151.
24. Reference of gel permeation chromatography with multi-angle light scattering detection. Available from: http://wyatt.com/
25. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus Brevifolia. J Am Chem Soc. 1971;93: 2325-2327.
26. Wang X, Zhao G, van S, et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol. 2010;65: 515-526.
27. Zhongling F, Zhao G, Yu L, Gough D, Howell SB. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol. 2010;65: 923-930.